Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.
Anthony A AmatoMichael G HannaPedro M MachadoUmesh A BadrisingGabriela Arredondo Hector ChinoyOlivier BenvenisteAnanda Krishna KaranamMin WuLászló B TankóAgnes Annette Schubert-TennigkeitDimitris A PapanicolaouThomas E LloydMerrilee NeedhamChristina LiangKatrina A ReardonMarianne de VisserDana P AschermanRichard J BarohnMazen M DimachkieJames A L MillerJohn T KisselBjörn E OskarssonNanette C JoycePeter Van den BerghJonathan BaetsJan L De BleeckerChafic KaramWilliam S DavidMassimiliano MirabellaSharon P NationsHans H JungElena PegoraroLorenzo MaggiCarmelo RodolicoMassimiliano FilostoAziz I ShaibaniKumaraswamy SivakumarNamita A GoyalMadoka Mori-YoshimuraSatoshi YamashitaNaoki SuzukiMasashi AokiMasahisa KatsunoHirokazu MorihataKenya MurataHiroyuki NoderaIchizo NishinoCarla D RomanoValerie S L WilliamsJohn VissingLixin Zhang Aubersonnull nullPublished in: Neurology (2021)
This study provides Class IV evidence that for patients with sIBM, long-term treatment with bimagrumab was safe, well-tolerated, and did not provide meaningful functional benefit. The study is rated Class IV because of the open-label design of extension treatment period 2.